Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 9/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5722925 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL936563 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL30711484 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7145238 | 0.89 | CA2 (0.46) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4823736 | 0.89 | CA2 (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4823732 | 0.89 | CA2 (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935393 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935402 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL10645332 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4936349 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6060482-A | SEROTONIN INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-09 | — | — | US | disclosed |
| US-5925662-A | OXIDASE INHIBITORS | SYNTHELABO (FR) | 1999-07-20 | — | — | US | disclosed |
| EP-0539803-B1 | Triazospirodecanone-methyl-chromans for the treatment of central nervous system illnesses | BAYER AG (DE) | 1999-01-07 | — | — | EP | disclosed |
| EP-0859776-A1 | COMPOUNDS DERIVED FROM OXAZOLIDIN-2-ONE AND PREPARATION AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1998-08-26 | — | — | EP | disclosed |
| US-5696137-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5696136-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5693653-A | ADMINISTERING AN ANTIDEPRESSANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| WO-1997017347-A1 | COMPOUNDS DERIVED FROM OXAZOLIDIN-2-ONE AND PREPARATION AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | disclosed |
| US-5545643-A | USEFUL FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| EP-0546389-B1 | Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1996-04-17 | — | — | EP | disclosed |
| EP-0546388-B1 | Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1996-03-27 | — | — | EP | disclosed |
| US-5371094-A | Azaheterocyclylmethyl-chromans for treating axiety | BAYER AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5326771-A | Piperidylmethyl-substituted chroman derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1994-07-05 | — | — | US | disclosed |
| EP-0546389-A1 | Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0546388-A1 | Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0539803-A1 | Triazospirodecanone-methyl-chromans for the treatment of central nervous system illnesses | BAYER AG (DE) | 1993-05-05 | — | — | EP | disclosed |